KDR and gastric cancer: The Rainbow trial indicated that adding ramucirumab, a monoclonal antibody VEGFR-2 antagonist, to paclitaxel improved OS in 665 GC patients (median 9.6 months vs 7.4 months stratified) (P = 0.017, HR 0.81, 95% CI: 0.68–0.96) [25].